Dermata Therapeutics Files 8-K: Material Agreements & Equity Sales
Ticker: DRMAW · Form: 8-K · Filed: Mar 28, 2025 · CIK: 1853816
| Field | Detail |
|---|---|
| Company | Dermata Therapeutics, Inc. (DRMAW) |
| Form Type | 8-K |
| Filed Date | Mar 28, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-action
Related Tickers: DRMA
TL;DR
DRMA filed an 8-K detailing material agreements and equity sales.
AI Summary
Dermata Therapeutics, Inc. announced on March 27, 2025, that it entered into a Material Definitive Agreement. The company also reported on Unregistered Sales of Equity Securities and Material Modifications to Rights of Security Holders. The filing includes Financial Statements and Exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions by Dermata Therapeutics, including definitive agreements and equity transactions, which could impact its financial structure and future operations.
Risk Assessment
Risk Level: medium — 8-K filings often signal significant corporate events that can introduce volatility and uncertainty for investors.
Key Players & Entities
- Dermata Therapeutics, Inc. (company) — Registrant
- March 27, 2025 (date) — Date of earliest event reported
- 3525 Del Mar Heights Rd., #322 (address) — Business and Mail Address
- San Diego, CA 92130 (address) — Business and Mail City, State, Zip
FAQ
What type of Material Definitive Agreement did Dermata Therapeutics enter into?
The filing does not specify the exact nature of the Material Definitive Agreement, only that one was entered into on March 27, 2025.
What were the details of the Unregistered Sales of Equity Securities?
The 8-K filing indicates that unregistered sales of equity securities occurred, but specific details such as the number of shares or price are not provided in this summary.
What modifications were made to the rights of security holders?
The filing states there were Material Modifications to Rights of Security Holders, but the specifics of these modifications are not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on March 27, 2025.
What is Dermata Therapeutics, Inc.'s Standard Industrial Classification?
Dermata Therapeutics, Inc.'s Standard Industrial Classification is PHARMACEUTICAL PREPARATIONS [2834].
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 28, 2025 regarding Dermata Therapeutics, Inc. (DRMAW).